SCHEMBL3217907

SCHEMBL3217907

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC(OCCC)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.49
PPARG P37231 6/20 0.49
CYP19A1 P11511 5/20 0.49
F7 P08709 4/20 0.49
F3 P13726 4/20 0.49
MAPT P10636 4/20 0.49
PPARD Q03181 4/20 0.49
PPARA Q07869 4/20 0.49
FFAR1 O14842 4/20 0.49
PTGS1 P23219 3/20 0.49
KMT2A Q03164 3/20 0.49
OXER1 Q8TDS5 3/20 0.49
CYP3A4 P08684 3/20 0.49
ALOX15 P16050 3/20 0.49
HSD17B10 Q99714 3/20 0.49
TDP1 Q9NUW8 3/20 0.49
L3MBTL1 Q9Y468 3/20 0.49
NR1I2 O75469 2/20 0.49
PTGS2 P35354 2/20 0.49
KDM4E B2RXH2 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3216964 0.99 ALDH1A1 (0.51) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL3225816 0.99 ALDH1A1 (0.51) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL3204814 0.90 ALDH1A1 (0.46) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL3208635 0.88 ALDH1A1 (0.51) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL3228292 0.87 ALDH1A1 (0.54) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL3225802 0.87 ALDH1A1 (0.54) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL28773266 0.87 TERT (0.49) PPARGCYP19A1F7F3MAPT
SCHEMBL13491236 0.86 ALDH1A1 (0.52) ALDH1A1PPARGCYP19A1F7F3
SCHEMBL4813269 0.86 ALDH1A1 (0.56) ALDH1A1PPARGCYP19A1F7F3
Icosabutate SCHEMBL298719 0.85 ALDH1A1 (0.51) ALDH1A1PPARGCYP19A1F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399516-B2 Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (PPAR) PRONOVA BIOPHARMA NORGE AS (NO) 2013-03-19 US disclosed
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PRONOVA BIOPHARMA NORGE AS (NO) 2010-02-11 US disclosed
EP-2094640-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). Pronova BioPharma Norge AS (NO) 2009-09-02 EP disclosed
WO-2008053331-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR). PRONOVA BIOPHARMA NORGE A/S (SE) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035990-A1 ALPHA-SUBSTITUTED OMEGA-3 LIPIDS THAT ARE ACTIVATORS OR MODULATORS OF THE PEROXISOME PROLIFERATORS-ACTIVATED RECEPTOR (PPAR) PPARG, PPARA, FFAR3 ALDH1A1 1088/4885PPARG 1/4885CYP19A1 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.